Adage Capital Partners’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $15.7M | Buy |
295,000
+100,000
| +51% | +$5.34M | 0.03% | 507 |
|
|
2025
Q1 | $7.89M | Buy |
+195,000
| New | +$7.89M | 0.01% | 631 |
|
|
2024
Q1 | – | Sell |
-275,000
| Closed | -$6.42M | – | 864 |
|
|
2023
Q4 | $6.42M | Sell |
275,000
-1,668,009
| -86% | -$38.9M | 0.01% | 660 |
|
|
2023
Q3 | $98.3M | Sell |
1,943,009
-1,105,868
| -36% | -$55.9M | 0.22% | 110 |
|
|
2023
Q2 | $142M | Buy |
3,048,877
+658,986
| +28% | +$30.8M | 0.31% | 75 |
|
|
2023
Q1 | $91.4M | Buy |
2,389,891
+1,064,914
| +80% | +$40.7M | 0.21% | 119 |
|
|
2022
Q4 | $72.6M | Buy |
1,324,977
+452,477
| +52% | +$24.8M | 0.17% | 143 |
|
|
2022
Q3 | $29.7M | Buy |
+872,500
| New | +$29.7M | 0.07% | 298 |
|
|
2020
Q1 | – | Sell |
-540,000
| Closed | -$12M | – | 724 |
|
|
2019
Q4 | $12M | Buy |
540,000
+15,000
| +3% | +$333K | 0.03% | 501 |
|
|
2019
Q3 | $11.9M | Buy |
525,000
+428,279
| +443% | +$9.74M | 0.03% | 485 |
|
|
2019
Q2 | $1.85M | Buy |
+96,721
| New | +$1.85M | ﹤0.01% | 666 |
|